Most Shared

WHAM13 - Search Results

The following is an archived video story. The text content of that video story is available below for reference. The original video has been deleted and is no longer available.

Cancer drug success raises questions about costs

Chicago (AP) -- For the first time in a decade, an experimental drug has extended the life of patients with advanced lung cancer who relapsed after standard chemotherapy. But the benefit of Eli Lilly and Co.'s drug Cyramza was just six extra weeks, on average, raising questions about the value of some costly new cancer medicines.

The drug is currently sold for stomach cancer and costs $6,000 per infusion.

The study is being discussed today at a cancer conference in Chicago.

 
Advertise with us!

Contests

Washington Times